On December 8, 2022, Hangzhou 1gene Technology Co., Ltd. closed the transaction. The company has received CNY 1,94,81,560 ($2,800,000) in its Series B round of funding led by new investor, ChengDa Pharmaceuticals Co., Ltd.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
20.21 CNY | +2.07% | +4.99% | -20.53% |
1st Jan change | Capi. | |
---|---|---|
-20.53% | 432M | |
+26.08% | 662B | |
+22.70% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 289B | |
+13.68% | 234B | |
+4.55% | 198B | |
-10.67% | 194B | |
+8.08% | 167B |
- Stock Market
- Equities
- 301201 Stock
- News ChengDa Pharmaceuticals Co., Ltd.
- Hangzhou 1gene Technology Co., Ltd. announced that it has received CNY 19.48156 million in funding from ChengDa Pharmaceuticals Co., Ltd.